European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the Treatment of Depressive Disorders

Patent provides protection for oral dosage forms of ketamine-based preclinical candidate, SPL801B, as a sole treatment and in combination with a serotonin modulator

Small Pharma Inc. (CVE: DMT)(OTCMKTS: DMTTF), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced that it has received European patent grant number EP 3 463 323 as acceptance for its European patent application No. 17 728640.8. The patent grants certain protections for oral dosage forms of a range of 2R,6R-hydroxynorketamine (“6-HNK”) based compounds, including the Company’s preclinical candidate SPL801B, for the treatment of depressive disorders.

We continue to experience rapid maturation both in our corporate profile and the progression of our pipeline of therapeutic candidates. Securing the patent rights to SPL801B, our preclinical ketamine-based candidate for the treatment of depression, allows us to securely investigate its commercial potential. This is the third patent to be granted in our growing IP portfolio which protects the Company’s rights to innovate and develop novel treatment candidates for mental health conditions.

Peter Rands, Chief Executive Officer of Small Pharma

The European patent office has determined the patentability of the novel dosage forms of 6-HNK, an active ketamine metabolite. The European patent also provides protection for a solid oral dosage form of SPL801B for administration, in combination with a serotonin modulator, for use in the treatment of depressive disorders. Early preclinical studies of SPL801B have shown signs of potential antidepressant effects without the psychoactive effects typically associated with ketamine.

About Small Pharma

Small Pharma is a neuropharmaceutical company specialized in IP-led development of novel treatments for mental health conditions, with a focus on depression. Small Pharma initiated a clinical program into N,N-dimethyltryptamine (“DMT”) assisted therapy in February 2021. This program includes a Phase I/IIa trial on the Company’s lead candidate alongside development of a robust pipeline of proprietary preclinical assets.

About SPL801B

SPL801B is a proprietary drug substance based on 6-HNK which is an active metabolite of ketamine. Scientific evidence suggests 6-HNK offers the potential for rapid antidepressant effects and may deliver an improved side effect profile to ketamine as an antidepressant.

To view the original press release in its entirety click here

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More